Abstract
Protein therapeutics offer distinct advantages over other classes of drugs largely due to the high level of target specificity and generally low toxicity. Problems have, however, been encountered with some protein therapeutics inducing undesirable immune responses in patients. This immunogenicity can produce pleiotropic effects including the development of a high affinity B cell-mediated humoral response that is often directed against the therapeutic. Opinions are divided as to the principal causes of clinical immunogenicity and, as a result, this area has been the subject of much research. One thing that has emerged as a result of this intense activity is the development of pre-clinical models that can provide a level of prediction of the immunogenic potential of novel protein therapeutics before administration in man.
Keywords: Immunogenicity, deimmunization, T cell epitopes, protein therapeutics
Current Drug Safety
Title: Pre-Clinical Considerations in the Assessment of Immunogenicity for Protein Therapeutics
Volume: 5 Issue: 4
Author(s): Matthew P. Baker and Francis J. Carr
Affiliation:
Keywords: Immunogenicity, deimmunization, T cell epitopes, protein therapeutics
Abstract: Protein therapeutics offer distinct advantages over other classes of drugs largely due to the high level of target specificity and generally low toxicity. Problems have, however, been encountered with some protein therapeutics inducing undesirable immune responses in patients. This immunogenicity can produce pleiotropic effects including the development of a high affinity B cell-mediated humoral response that is often directed against the therapeutic. Opinions are divided as to the principal causes of clinical immunogenicity and, as a result, this area has been the subject of much research. One thing that has emerged as a result of this intense activity is the development of pre-clinical models that can provide a level of prediction of the immunogenic potential of novel protein therapeutics before administration in man.
Export Options
About this article
Cite this article as:
Baker P. Matthew and Carr J. Francis, Pre-Clinical Considerations in the Assessment of Immunogenicity for Protein Therapeutics, Current Drug Safety 2010; 5 (4) . https://dx.doi.org/10.2174/157488610792246000
DOI https://dx.doi.org/10.2174/157488610792246000 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity
Current Topics in Medicinal Chemistry Effects of Vitamin A Deficiency and Opioids on Parvalbumin + Interneurons in the Hippocampus of the HIV-1 Transgenic Rat
Current HIV Research Multimodality Imaging in Acute Ischemic Stroke
Current Medical Imaging Enterovirus D-68 Molecular Virology, Epidemiology, and Treatment: an Update and Way Forward
Infectious Disorders - Drug Targets Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy Echinocandins for the Nursery: An Update
Current Drug Metabolism Chronic HIV-1 Tat and HIV Reduce Rbfox3/NeuN: Evidence for Sex- Related Effects
Current HIV Research Chemokines and Malaria Infection
Current Immunology Reviews (Discontinued) The Gut Microbiota and the Emergence of Autoimmunity: Relevance to Major Psychiatric Disorders
Current Pharmaceutical Design Catatonia Due to a General Medical Condition (Organic Catatonia)
Current Psychiatry Reviews Biomedical Application of Polymers: A Case Study of Non-CNS Drugs Becoming CNS Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Nanomedicine in Therapeutic Intervention of Tuberculosis Meningitis
Current Nanoscience Proteomics and Protein Analyses of Ovine and Caprine Body Fluids: Current Studies and Future Promises
Current Protein & Peptide Science Abnormal Functional and Structural Asymmetry as Biomarker for Schizophrenia
Current Topics in Medicinal Chemistry The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Current Neuropharmacology New Perspectives in HCV Therapy: Entry Inhibitors
Recent Patents on Anti-Infective Drug Discovery Role of Unani Medicines in Cancer Control and Management
Current Drug Therapy Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Angiopoietin-1 and C16 Peptide Attenuate Vascular and Inflammatory Responses in Experimental Allergic Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Biological Activity of Cytokines: An Evolutionary Perspective
Current Pharmaceutical Design